The Use of Noninvasive Velacur® for Discriminating between Volunteers and Patients with Chronic Liver Disease: A Feasibility Study by Michael P. Curry, Edward Tam, Caitlin Schneider, Noha Abdelgelil, Tarek Hassanien, Nezam H. Afdhal

Get full text

Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD by Joana Vieira Barbosa, Scott Milligan, Andrew Frick, Jeremy Broestl, Zobair Younossi, Nezam H. Afdhal, Michelle Lai

Get full text

A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease by Christopher J. Danford, Margery A. Connelly, Irina Shalaurova, Misung Kim, Mark A. Herman, Imad Nasser, James D. Otvos, Nezam H. Afdhal, Z. Gordon Jiang, Michelle Lai

Get full text

Methods and validation of velacur determined fat fraction in patients with MASLD by Mohammad Honarvar, Julio Lobo, Caitlin Schneider, Samuel Klein, Gordon I. Smith, Rohit Loomba, Alnoor Ramji, Tarek Hassanein, Eric M. Yoshida, Emily Pang, Michael P. Curry, Nezam H. Afdhal

Get full text

Differential Associations of Circulating MicroRNAs With Pathogenic Factors in NAFLD by Ghideon Ezaz, Hirsh D. Trivedi, Margery A. Connelly, Claudia Filozof, Kellie Howard, Mark L.Parrish, Misung Kim, Mark A. Herman, Imad Nasser, Nezam H. Afdhal, Z. Gordon Jiang, Michelle Lai

Get full text

First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide by Calvin Q. Pan, Nezam H. Afdhal, Victor Ankoma‐Sey, Ho Bae, Michael P. Curry, Douglas Dieterich, Lynn Frazier, Andrew Frick, Hie‐Won Hann, W. Ray Kim, Paul Kwo, Scott Milligan, Myron J. Tong, K. Rajender Reddy

Get full text